Fundsmith LLP’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$824M Sell
1,465,786
-410,249
-22% -$263M 6.42% 7
2025
Q4
$1.27B Sell
1,876,035
-734,422
-28% -$500M 7.42% 3
2025
Q3
$1.67B Sell
2,610,457
-28,832
-1% -$17.5M 8.43% 2
2025
Q2
$1.42B Sell
2,639,289
-9,042
-0.3% -$4.32M 6.15% 5
2025
Q1
$1.11B Sell
2,648,331
-14,524
-0.5% -$6.31M 5.06% 8
2024
Q4
$1.1B Sell
2,662,855
-1,307
-0% -$573K 4.69% 10
2024
Q3
$1.35B Buy
2,664,162
+970
+0% +$471K 5.32% 7
2024
Q2
$1.3B Sell
2,663,192
-51,570
-2% -$25.9M 5.29% 7
2024
Q1
$1.47B Sell
2,714,762
-14,155
-0.5% -$7.74M 5.74% 5
2023
Q4
$1.51B Sell
2,728,917
-235,637
-8% -$111M 6.34% 4
2023
Q3
$1.3B Buy
2,964,554
+3,003
+0.1% +$1.5M 5.89% 7
2023
Q2
$1.49B Buy
2,961,551
+7,355
+0.2% +$3.52M 6.24% 5
2023
Q1
$1.48B Sell
2,954,196
-489,536
-14% -$234M 6.37% 4
2022
Q4
$1.4B Sell
3,443,732
-177,045
-5% -$68.7M 6.42% 4
2022
Q3
$1.18B Buy
3,620,777
+1,902
+0.1% +$699K 5.6% 5
2022
Q2
$1.27B Buy
3,618,875
+813
+0% +$332K 5.6% 5
2022
Q1
$1.98B Sell
3,618,062
-624,221
-15% -$328M 6.8% 2
2021
Q4
$2.79B Buy
4,242,283
+81
+0% +$50.8K 6.82% 2
2021
Q3
$2.64B Sell
4,242,202
-260
-0% -$175K 7.29% 3
2021
Q2
$2.68B Buy
4,242,462
+21,850
+0.5% +$12.1M 7.42% 3
2021
Q1
$2.07B Sell
4,220,612
-5,816
-0.1% -$2.91M 6.57% 3
2020
Q4
$2.11B Sell
4,226,428
-6,387
-0.2% -$2.86M 7% 3
2020
Q3
$1.66B Sell
4,232,815
-7,896
-0.2% -$2.92M 6.5% 4
2020
Q2
$1.4B Sell
4,240,711
-4,516
-0.1% -$1.31M 6.11% 4
2020
Q1
$1.03B Sell
4,245,227
-346,672
-8% -$90.5M 5.79% 6
2019
Q4
$1.2B Buy
4,591,899
+35,883
+0.8% +$9.46M 5.67% 10
2019
Q3
$1.24B Buy
4,556,016
+85,978
+2% +$23.9M 6.33% 7
2019
Q2
$1.23B Buy
4,470,038
+2,697
+0.1% +$665K 6.41% 4
2019
Q1
$999M Buy
4,467,341
+35,049
+0.8% +$7.24M 5.68% 10
2018
Q4
$1.11B Buy
4,432,292
+5,649
+0.1% +$1.16M 7.03% 3
2018
Q3
$1.11B Sell
4,426,643
-2,461
-0.1% -$597K 7.41% 3
2018
Q2
$965M Buy
4,429,104
+1,447
+0% +$298K 7.18% 4
2018
Q1
$847M Buy
4,427,657
+22,901
+0.5% +$4.23M 6.99% 6
2017
Q4
$689M Sell
4,404,756
-14,088,162
-76% -$2.22B 5.9% 9
2017
Q3
$1.58B Buy
18,492,918
+14,046,878
+316% +$2.22B 15.34% 1
2017
Q2
$718M Sell
4,446,040
-34,167
-0.8% -$5.55M 7.53% 5
2017
Q1
$693M Buy
4,480,207
+3,341
+0.1% +$461K 8.05% 1
2016
Q4
$529M Sell
4,476,866
-14,017
-0.3% -$1.6M 6.96% 4
2016
Q3
$506M Buy
4,490,883
+21,547
+0.5% +$2.27M 6.92% 3
2016
Q2
$415M Buy
4,469,336
+258,657
+6% +$22.2M 6.57% 7
2016
Q1
$330M Buy
4,210,679
+1,719,511
+69% +$124M 7.1% 5
2015
Q4
$182M Buy
2,491,168
+1,610,682
+183% +$115M 4.56% 12
2015
Q3
$65.4M Buy
880,486
+813,646
+1,217% +$58.3M 1.99% 16
2015
Q2
$4.29M Buy
66,840
+15,854
+31% +$1.1M 0.13% 18
2015
Q1
$3.94M Buy
+50,986
New +$3.97M 0.13% 19

Other funds holding IDXX

Fundsmith LLP's IDXX Position: Q1 2026 in Review

Fundsmith LLP reduced its Idexx Laboratories (IDXX) stake by 22% in Q1 2026, selling an estimated $263M and leaving 1,465,786 shares worth $824M. The position accounts for 6.42% of the portfolio, ranked #7.

Fundsmith LLP first reported a position in IDXX in Q1 2015 and has held it in 45 quarters since. The position peaked at $2.79B in Q4 2021. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

  • Fundsmith LLP held 1,465,786 shares of Idexx Laboratories worth $824M as of Q1 2026.
  • Fundsmith LLP sold 410,249 Idexx Laboratories shares in Q1 2026, an estimated $263M.
  • Idexx Laboratories made up 6.42% of Fundsmith LLP's portfolio in Q1 2026, its #7 holding.
  • Fundsmith LLP first reported a position in Idexx Laboratories in Q1 2015 and has held it in 45 quarters since.
  • Fundsmith LLP's Idexx Laboratories position peaked at $2.79B in Q4 2021.
  • 1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Fundsmith LLP's 13F filing for Q1 2026, filed 15 May 2026.